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Abstract: Hereditary haemorrhagic telangiectasia (HHT) is characterised by arteriovenous malforma-
tions (AVMs). These vascular abnormalities form when arteries and veins directly connect, bypassing
the local capillary system. Large AVMs may occur in the lungs, liver and brain, increasing the risk
of morbidity and mortality. Smaller AVMs, known as telangiectases, are prevalent on the skin and
mucosal lining of the nose, mouth and gastrointestinal tract and are prone to haemorrhage. HHT is
primarily associated with a reduction in endoglin (ENG) or ACVRL1 activity due to loss-of-function
mutations. ENG and ACVRL1 transmembrane receptors are expressed on endothelial cells (ECs)
and bind to circulating ligands BMP9 and BMP10 with high affinity. Ligand binding to the receptor
complex leads to activation of the SMAD1/5/8 signalling pathway to regulate downstream gene
expression. Various genetic animal models demonstrate that disruption of this pathway in ECs results
in AVMs. The vascular abnormalities underlying AVM formation result from abnormal EC responses
to angiogenic and haemodynamic cues, and include increased proliferation, reduced migration
against the direction of blood flow and an increased EC footprint. There is growing evidence that
targeting VEGF signalling has beneficial outcomes in HHT patients and in animal models of this
disease. The anti-VEGF inhibitor bevacizumab reduces epistaxis and has a normalising effect on high
cardiac output in HHT patients with hepatic AVMs. Blocking VEGF signalling also reduces vascular
malformations in mouse models of HHT1 and HHT2. However, VEGF signalling is complex and
drives numerous downstream pathways, and it is not yet clear which pathway (or combination of
pathways) is critical to target. This review will consider the recent evidence gained from HHT clinical
and preclinical studies that are increasing our understanding of HHT pathobiology and informing
therapeutic strategies.
Keywords: BMP9/10; ENG; ACVRL1; VEGF; angiogenesis; arteriovenous malformation
1. Introduction
Hereditary Haemorrhagic Telangiectasia (HHT) is an inherited vascular disorder
affecting up to 1 in 5000 people. It is an autosomal dominant disorder and the vast majority
of patients (>85%) have inherited one allele encoding nonfunctional endoglin (ENG) or
activin receptor-like kinase 1 (ACVRL1, also known as ALK1) allele [1]. A minority of
HHT cases are due to mutations in SMAD4 or BMP9 (GDF2), but these have somewhat
different clinical presentations. SMAD4 patients have a combined Juvenile Polyposis–HHT
syndrome, whilst BMP9 patients display a mild HHT-like phenotype [2,3]. This review will
focus on the two major patient groups, HHT1 and HHT2 that are caused by loss-of-function
(LOF) mutations in ENG and ACVRL1, respectively.
HHT1 and HHT2 patients develop very similar clinical symptoms that result from
sporadic vascular malformations, with clinical diagnosis based on the “Curacao criteria”.
Patients with at least three of the following features are considered to have a definitive
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diagnosis of HHT: (1) multiple mucocutaneous telangiectases, (2) recurrent nosebleeds,
(3) visceral organ arteriovenous malformations (AVMs) and (4) a first degree relative
with HHT. Where possible, this diagnosis is confirmed by genetic testing. Telangiectases
are small arteriovenous connections found on the skin and mucosal surfaces and are
prone to bleeding in the nose and gastrointestinal (GI) tract. In fact, epistaxis from nasal
telangiectases is the most highly penetrant phenotype, present in almost all young adults
with HHT, and anaemia may be sufficiently severe to necessitate regular iron or blood
transfusions. Larger AVMs may be present in the lung, liver and neural tissues. HHT1 and
HHT2 patients differ in the incidence of affected tissues, with AVMs in the lung and brain
more common in HHT1, whilst a spectrum of hepatic vascular malformations including
AVMs are more common in HHT2 [4,5]. The reasons for these differences are not yet
known.
2. BMP9/10 Signalling
ENG and ACVRL1 proteins are expressed on the endothelial cell (EC) surface. They
are also found in other cell types, for example, in fibroblasts, but overwhelming evidence
from preclinical studies points to the critical nature of their endothelial role in protecting
against vascular malformations in HHT [6]. LOF mutations in ENG and ACVRL1 lead to
disruption of bone morphogenetic protein 9/10 (BMP9/10) signalling. BMP9 (encoded by
GDF2) and BMP10 are ligands of the TGFβ superfamily produced by the liver and right
cardiac atrium, respectively, and released into the circulation in active forms [7–10]. ENG
and ACVRL1 proteins have a high binding affinity for both BMP9 and BMP10 [11,12] that
initiates signalling [13]. ENG has a large glycosylated extracellular domain that can form
an ENG–BMP9/10 complex [14] and provides an EC surface reservoir of bound ligand [15].
To promote signalling, ENG forms a BMP9/ENG/ACVRL1 protein complex (or equivalent
complex with BMP10 or potentially even a BMP9/10 dimer [16]). In this way, ENG acts
as a coreceptor to promote BMP9/10 signalling through the signalling receptor kinase
ACVRL1. ENG protein is released from the complex following recruitment of the type II
receptor (either BMPR2 or ACTRIIB or ACTRIIA) which phosphorylates ACVRL1 kinase
to activate and propagate the signalling cascade via activation of transcription factors
SMAD1/5/8 (Figure 1). SMAD4 then associates with phospho-SMAD1/5/8 to form a
SMAD transcription factor complex which shuttles to the nucleus to regulate genes that
promote quiescence and migration. In parallel, TGFBR2/ALK5 stimulation following
binding of TGFβ ligand results in phosphorylation of SMAD2/3. Phospho-SMAD2/3
then interacts with SMAD4 in order to move to the nucleus to regulate multiple genes
including those that promote extracellular matrix secretion. Disruption of the BMP9/10
pathway leads to the endothelial cell defects seen in HHT and may be partly explained by
a disrupted balance of BMP9/10 and TGF-β1 signalling pathways.
The critical importance of this pathway in HHT is confirmed by evidence from com-
bined loss of BMP9 and BMP10 activities in mouse models that recapitulate the vascular
malformations typical of HHT [17,18]. The requirement for loss of both ligands to generate
AVMs pointed to functional redundancy. However, BMP10, but not BMP9, plays the critical
role in maintaining normal vascular architecture in zebrafish [19,20]. Work in mice suggests
some differences between BMP9 and BMP10 functions, where loss of BMP9 affects the
lymphatic but not blood vasculature [21], and loss of BMP10 is embryonic lethal at E10.5
due to failure of heart development [8]. Replacing the murine BMP10 coding sequence with
that of BMP9 partially rescues defects in heart development, but not sufficiently to survive
to birth, pointing to an essential role for BMP10 in cardiogenesis [22]. Further investigations
are required to interrogate the overlapping and different functions of BMP9 and BMP10
signalling in ECs in vivo, as they appear to be very similar in vitro [10]. Indeed, signalling
outcomes may depend on type II receptor availability as BMP9 shows a preference for
ACTRIIB over BMPR2, and low affinity for ACTRIIA, whilst BMP10 has similar binding
affinity for all three type II receptors [23]. A better understanding of the roles of BMP9
and BMP10 in the vasculature would inform potential ligand treatment strategies to rescue
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clinical features of HHT1 (see below). Moving downstream of the signalling pathway,
the critical importance of the canonical SMAD1/5/8 pathway in protecting ECs against
vascular malformations is shown by the HHT-like phenotype in SMAD4 LOF mutation
patients [2], and by the retinal AVMs that develop in neonatal mice with endothelial loss of
either SMAD4 or SMAD1/5 [24,25].
Figure 1. Schematic summary of BMP9/10 and TGFβ1 signalling pathways in endothelial cells. Figure created with
BioRender (https://biorender.com/).
Whilst considering the role of this pathway in HHT, it is important to note that
there is some confusion in the literature regarding the critical ligands that protect against
HHT, because TGFβ1 and 3 were originally thought to be the primary ligands for the
ENG/ACVRL1 pathway. As discussed above, it is now clear that BMP9 and BMP10 have
much higher affinities for ENG and ACVRL1 proteins than TGFβ1. It is even possible
that rather than TGFβ1 signalling being reduced following depletion of ENG or ACVRL1
protein activity, TGFβ1 signalling may actually be increased due to an imbalance between
BMP9/10 and TGFβ1 signalling in ECs (Figure 1).
3. Aetiology of HHT Disease
Although there is a growing consensus that HHT is caused by reduced BMP9/10
signalling in ECs, it is not yet clear why the vascular lesions are localised to specific organs
and tissues. Nasal telangiectases and nosebleeds seem to be the most highly penetrant
feature affecting over 90% of young HHT adults. Dermal and GI telangiectases accrue
later in adult life, whilst pulmonary and cerebral AVMs may be present from birth, usually
reaching their final size by adult life [26,27]. The first point to emphasise here is that the
majority of the vascular architecture in HHT1/2 patients appears to be normal, supporting
the conclusion that one wild type allele (for ENG or ACVRL1) is sufficient for development,
maintenance and function of the vast majority of the vasculature. Therefore, to explain the
focal nature of vascular lesions, a local second genetic hit has been postulated, and recent
evidence has indeed confirmed biallelic loss of ENG or ACVRL1 gene function in dermal
telangiectases from HHT1 and HHT2 patients [28]. This mechanism is yet to be confirmed
in larger AVMs from HHT patients when such tissue becomes available. However, this
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finding is entirely consistent with evidence from preclinical models that reproducibly
develop AVMs when functional Eng or Acvrl1 genes are deleted from ECs, but rarely when
mice are heterozygous carriers of Eng or Acvrl1 LOF mutations [6]. This second genetic hit
event to generate ENG or ACVRL1 null ECs will likely be a stochastic event that is entirely
consistent with HHT vascular lesions that accrue with age such as dermal telangiectases.
If biallelic loss of ENG or ACVRL1 drives the formation of sporadic vascular lesions in
HHT, this only partly explains the phenotypic complexity of this disease. An explanation is
also required as to the tissue location preference for AVMs and telangiectases. Considering
the nasal telangiectases first, these lesions are the most highly penetrant defect in HHT1
and HHT2, and the nasal mucosal tissue is also an area of acute inflammation during
frequent respiratory infections such as the common cold. Local inflammation would
provide two additional stimuli that may be relevant to initiate telangiectasis formation.
Firstly, inflammation triggers removal of the endothelial glycocalyx, and is associated with
local release of inflammatory cytokines such as tumour necrosis factor-α (TNFα). This
cytokine triggers events leading to cleavage of the extracellular domain of ENG protein,
which is released as a soluble form into the circulation [29]. As HHT1 patients have
baseline levels of 50% of the normal levels of ENG protein [30], then protein cleavage
during inflammation may cause this to drop below the levels required to maintain the
normal vascular architecture. It is interesting to note in this context that genetic variants of
ADAM17, which encodes a major regulator of TNFα activity, are associated with pulmonary
disease severity in HHT1 [31]. Secondly, inflammation resulting from infection or tissue
injury generates a proangiogenic stimulus that has been shown in preclinical models to
be required for AVM formation [6,32]. Organs that are frequently affected in HHT are all
exposed to environmental and/or inflammatory insults. This is most obvious for the lung,
skin, oronasal and GI tract. However, the liver is also exposed to blood draining from
the gut which is rich in antigenic material including microbial debris. As a result, local
inflammation is a normal part of liver homeostasis [33]. In addition, although cerebral
tissue would normally be protected from environmental insults, there is an increased risk of
embolic stroke and cerebral abscess caused by microthrombi passing through lung AVMs,
even when these are small and clinically silent [26,27]. It therefore logically follows that
there is an increased risk of proinflammatory microthrombi reaching the brain that may be
insufficient to cause clinical stroke or abscess, but still provide sufficient pathophysiological
proinflammatory trigger for vessel remodelling to form brain AVMs (BAVMs). Therefore,
it may be no coincidence that lung and brain AVMs are both present in HHT1 patients
more frequently than HHT2 patients. Furthermore, the variability of clinical symptoms
even within the same HHT family carrying the same mutation (in ENG or ACVRL1) can be
explained by this complex pathogenesis that depends on the timing of the second hit—a
stochastic mutation event and/or exposure to an inflammatory or other environmental
stimulus that promotes angiogenesis. Indeed, developmental angiogenesis may help
drive the formation of congenital AVMs in the presence of biallelic ENG or ACVRL1 LOF
mutations. Ultimately, however, the precise reasons for the specific tissue distribution of
vascular lesions in HHT remain to be uncovered in detail in future work.
Once an abnormal arteriovenous shunt is formed it becomes extremely challenging to
reverse due to the increased blood flow. Added to this is evidence that loss of ACVRL1
signalling alters the endothelial response to shear stress [34,35]. Analysis of zebrafish
embryos harbouring a LOF mutation in acvrl1 showed increased EC numbers in cerebral
arteries that further increased in response to blood flow to generate stabilised AVMs [35].
This increase in EC number to generate an AVM is not due to increased proliferation,
but rather to reduced migration of ECs against blood flow leading to an accumulation of
ECs that would normally have migrated towards the heart [36]. This reduced migration
defect has also been confirmed in a mouse model of HHT1 [37]. In this way, due to a
failure of normal EC migration against blood flow, congenital AVMs may further enlarge
during developmental angiogenesis. Furthermore, additional local secondary events likely
come into play as blood shunting via an AVM and bypassing a local capillary bed cannot
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efficiently exchange oxygen leading to local tissue hypoxia. Low oxygen leads to a local
increased expression of many genes, including VEGF, which potentially drives a positive
feedback scenario in HHT causing further angiogenic stimulation and AVM expansion.
Another important contributory element to AVM formation is the disruption of
crosstalk between ECs and pericytes. Following loss of ENG, there is reduced pericyte–EC
contact that may affect vasoregulation and vessel stability in HHT. Evidence from mouse
models of HHT shows reduced vascular smooth muscle coverage and reduced pericyte–
endothelial integration leading to vessel instability [38,39]. Reduced pericyte number and
coverage have also been reported in sporadic brain AVMs (BAVMs) [40], and may also be
the case in BAVMs in HHT patients.
To summarise, in addition to genetic loss of ENG or ACVRL1, developmental angio-
genesis, blood flow and local environmental triggers driving neovessel formation, such as
hypoxia and inflammation, are critical players driving the formation of AVMs in HHT.
4. Overlapping Endothelial Cell Abnormalities in HHT and Spontaneous BAVMs
Although up to 5% HHT patients develop BAVMs, the majority of BAVMs in pa-
tients presenting at neurology clinics are spontaneous. There is an inherent high risk of
haemorrhage from a BAVM which accounts for the majority of haemorrhagic strokes in
young adults. This risk has driven major efforts to better understand BAVM pathobiology,
and in light of recent progress in this area it is important to consider whether there are
overlaps between the downstream molecular changes that give rise to spontaneous and
HHT BAVMs. Recent seminal work has revealed that somatic activating mutations in
KRAS are associated with the majority of spontaneous BAVMs [41]. These constitutively
active (CA) KRAS mutations are present in ECs of spontaneous BAVMs in a mosaic fashion.
This parallels evidence from a mouse model of HHT1, where mosaicism for Eng mutations
in ECs is sufficient to generate AVMs [37]. Thus, only a proportion of ECs need to harbour
a new mutant allele to develop AVMs in both HHT and in spontaneous BAVMs. In HHT,
the new mutation is a loss of the second functional ENG or ACVRL1 allele, whereas in
spontaneous brain AVMs it is gain of a CA-KRAS mutation. It is striking that ECs with
gain of KRAS activity or LOF ENG mutations both show elevated phospho-ERK activity,
suggesting that this may be a common pathway associated with AVM formation [42,43].
Furthermore, as inhibiting MEK signalling can reverse established AVMs due to activated
KRAS in the zebrafish model [42], this finding may be relevant to HHT (as discussed
below). However, it is not yet clear whether the proproliferative role of the activated
RAS/RAF/MEK/ERK pathway makes a direct contribution to AVMs [42]. Similarly, it is
not known to what extent loss of the antiproliferative role of BMP9 signalling in the absence
of ENG or ACVRL1 proteins drives the increased EC proliferation seen in telangiectases
from HHT2 patients and in AVMs in preclinical models of HHT [17,44–47]. Nevertheless,
the similarities in cellular responses in AVMs in HHT and spontaneous BAVMs suggest
that scientific progress in these two fields may be mutually informative [48].
5. Treatment Options for HHT
There are currently limited options for treating HHT. To date, the majority of therapeu-
tic approaches in severe disease have focussed on invasive procedures to cauterise bleeding
telangiectases or occlude phenotypic AVMs (where accessible) to reduce disease symptoms
or risk of complications such as stroke. Depending on the location of symptomatic vascular
lesions and severity of symptoms, the feeding artery of an AVM can be physically occluded
to prevent arteriovenous shunting of blood. This is frequently achieved by implantation
of intravascular metal coils to occlude pulmonary AVMs to successfully restore blood
oxygenation levels. However, access to symptomatic AVMs in the brain and liver is more
challenging and presents a higher risk. Importantly, embolization of asymptomatic AVMs
is not recommended in HHT. Liver transplant is recommended where hepatic VMs are
sufficiently severe to cause high output heart failure. The advances in understanding the
molecular and cellular defects that drive HHT and the availability of reproducible preclini-
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cal models have driven further investigations to identify optimal pharmaceutical strategies
to prevent or reverse established AVMs. Translation of these fundamental findings to the
clinic ultimately depends on the availability of suitable safe drugs. These research efforts
are summarised below and in Table 1.
Table 1. Pharmaceutical rescue of Hereditary haemorrhagic telangiectasia (HHT)-related phenotypes in patients and
preclinical models.
Drug Target Number of HHT Patients Outcomes Reference
Bevacizumab (Avastin) Anti-VEGFA antibody 24
Reduced epistaxis and
improved cardiac function in
liver VM patients with HOHF
[49]




24 (+24 placebo) Reduced epistaxis [51]
Pazopanib TKI 7










7 Reduced epistaxis [38]
Drug Target Mouse Model Outcomes Reference
Wortmannin, Pictilisib PI3K inhibitor
Acvrl1-iKOe and Eng-iKOe
neonates








and reversed retinal AVMs
[54]
DC101 Anti-VEGFR2 antibody Eng-iKOe adult Prevents AVMs and HOHF [43]
G6.31 Anti-VEGFA antibody Acvrl1-iKOe adult
Prevention of wound induced
dermal AVMs; possible







Each drug alone significantly
improved Hb and GI bleeding
but did not prevent
wound-induced skin AVMs.
[56]
SU5416 VEGFR2 inhibitor Eng-iKOe neonate








Increased SM coverage of
dermal and cerebral vessels,
reduced cerebral haemorrhage
[38,57]
LC10 ANGPT2 inhibitor Smad4-iKOe neonate Prevents retinal AVMs [58]
Abbreviations: GI, gastrointestinal; Hb, haemoglobin; HOHF, high output heart failure; -iKO(e), inducible gene knockout (Endothelial Cell
(EC)-specific); TKI, tyrosine kinase inhibitor. VM: vascular malformation; AVM: arteriovenus malformation.
5.1. Increasing Expression of ENG or ACVRL1 Genes
Using a myoblast cell line stably expressing an Id1 reporter (C2C12BRA) to screen 700
FDA-approved drugs, Tacrolimus (also known as FK506 or Fujimycin) was identified as a
potent activator of the BMP9-ACVRL1-BMPR2-SMAD1/5/8 signalling cascade [59]. This
drug is widely used clinically as an immunosuppressant, for example, in organ transplan-
tion, but has also been shown to increase ENG and ACVRL1 expression [60]. Tacrolimus is
also suggested to be useful in the treatment of pulmonary arterial hypertension (PAH), a
disease associated with genetic defects in BMP signalling. Three end stage PAH patients
all showed stabilized cardiac function and an increase in BMPR2 expression following
Tacrolimus treatment [61]. A case report shows clinical improvements following Tacrolimus
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therapy in an ACVRL1 patient with a combined HHT PAH syndrome [62]. However, a
recent randomised trial showed only minor effects of topical Tacrolimus nasal treatment
on epistaxis [51] and further work is needed to evaluate this therapy in HHT.
Recent work has shown that ectopic expression of human/mouse ACVRL1 in mouse
models of HHT1 and HHT2 can prevent AVMs [63]. Although this finding is in line with
the recessive nature of LOF ENG and ACVRL1 mutations in the presence of exogenous
ACVRL1 expression, this type of approach is difficult to apply clinically. If Tacrolimus
increases expression of the unaffected allele in HHT patients, this has the potential to be
beneficial, but only if the vascular lesions in HHT are caused by haploinsufficiency. This
may be true if a localised bout of inflammation led to a temporary loss of ENG or ACVRL1
protein, but if the majority of lesions arise from biallelic LOF mutations (due to the genetic
two hit mechanism), this strategy would not be useful. Increased understanding of disease
mechanisms in HHT patients is clearly essential and awaits genetic analysis of larger AVMs,
as discussed above.
Patient-specific mutant allele correction using a CRISPR/Cas9 approach is possible in
principle but is currently too high risk due to risk of uncontrolled off-target effects. In terms
of a personalised gene therapy approach, patient-specific exon skipping has moved to
clinical trials in genetic diseases such as Duchenne muscular dystrophy (DMD). This uses
a therapeutic antisense oligonucleotide that allows the transcriptional machinery to bypass
pathogenic DMD mutations in specific exons (amenable to exon skipping) to produce
a slightly shorter but still partially functional dystrophin protein [64]. This approach
is less likely to be useful for ACVRL1 and ENG, where there are no known redundant
protein regions. However, treatments enabling stop codon read-through [65] may be
applicable to specific HHT1 and HHT2 patients where the disease-causing mutation is a
premature stop codon in the ENG or ACVRL1 coding region. This type of mutation leads
to premature termination of translation and a truncated nonfunctional ENG or ACVRL1
protein. Although its efficacy is highly variable, stop codon readthrough is now under
evaluation in clinical trials for some cystic fibrosis patients and may offer hope to those
HHT patients with disease-causing nonsense mutations.
5.2. Increasing BMP9/10 Ligand Availability
As discussed above, HHT1 is likely due to a reduced level of BMP9/10 signalling
through depleted ENG protein levels. Therefore, it may be possible to bypass the require-
ment for ENG and increase BMP9/10 signalling through ACVRL1 kinase by increasing
the amount of circulating BMP9/10 ligand. Clearly, this approach would be ineffective
to bypass local loss of ACVRL1 signalling kinase activity in HHT2. However, a major
potential problem using exogenous BMP9/10 is the propensity of both these ligands to
drive heterotrophic bone formation [10]. Some exciting progress has been made in reducing
the osteogenic properties of BMP9 whilst maintaining its EC signalling properties [10] and
potentially similar changes could be applied to BMP10, which may have a higher protective
effect in HHT [20].
5.3. Targeting Proangiogenic Growth Factor Signalling
VEGF(A) signals through VEGFR2 receptor to activate a range of downstream path-
ways regulating cell metabolism, proliferation, survival and permeability (Figure 2).
BMP9/10 signalling affects the endothelial cell’s response to VEGF stimulation in at least
two ways. First, BMP9/10 signalling prevents inactivation of PTEN, consequently inhibit-
ing PI3K activity and reducing AKT activation responses. Second, downstream BMP9/10
signalling inhibits VEGF signalling outcomes in ways that remain to be defined but require
a minimum of two hours, implying requirement for downstream gene expression [44]. In
consequence, loss of BMP9/10 signalling leads to an untempered response of VEGF such
as increased endothelial cell proliferation, which contributes to AVM formation. Drugs
targeting VEGFA/VEGFR2 signalling and downstream mediators that have shown benefit
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in HHT (patients and/or preclinical models) are indicated in Figure 2 and summarised in
the table.
A marked improvement of HHT disease symptoms was noted when the anti-VEGF
antibody Bevacizumab was used to treat cancer in an HHT patient [66]. This initial
serendipitous finding led to the realisation that reducing VEGF activity was beneficial in
HHT and was followed up by successful (nonrandomised) clinical trials showing improved
cardiac function in HHT patients with hepatic VMs and reduced epistaxis [49,50]. A major
caveat is that to be effective intravenous Bevacizumab is repeated over a substantial period
and can incur significant side effects including hypertension, thrombosis and impaired
healing. Targeting VEGF signalling has also been shown to be effective in protecting against
AVM formation in many animal models of HHT [37,43,55]. However, VEGF signalling
is complex and drives numerous downstream pathways, and it is not yet clear which
pathway (or combination of pathways) is critical to target. Furthermore, there is limited
understanding to date of the molecular interaction between VEGF signalling and BMP9/10
signalling, or how this is disrupted in HHT. Advances in this area are essential to optimise
and improve therapies targeting VEGF signalling.
Multisite phosphorylation of the VEGFR2 receptor following VEGF ligand binding
leads to activation of various signalling pathways that regulate EC proliferation, migration
and adhesion, all of which are required to regulate normal angiogenic responses. These
downstream pathways include the phospholipase Cγ (PLCγ)–ERK1/2 pathway, the PI3K–
AKT–mTOR pathway and CDC42-p38 pathway (Figure 2). Although BMP9 is known to
counter the proangiogenic effects of VEGF and act as a circulating vascular quiescence
factor [12,67], it is not known how exactly this is achieved by crosstalk between BMP9/10
and VEGF signalling pathways. There may simply be increased circulating levels of VEGF
in HHT patients [68], perhaps due to local tissue hypoxia (as discussed above) or to an
altered balance of ALK5/ACVRL1 signalling [69] and it is this increased VEGF that disturbs
the balance of VEGF signalling to generate AVMs. However, this systemic increase in VEGF
would not in itself explain the localised nature of AVMs in HHT.
Figure 2. Schematic summary of crosstalk between BMP9/10 and VEGF signalling pathways in endothelial cells. Figure
created with BioRender (https://biorender.com/).
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EC-based studies in vitro have been used to interrogate the molecular interactions
between BMP9/10 and VEGF signalling. BMP9 inhibits PI3K signalling by increasing
activity of PTEN, a phosphatase that decreases PI3K activity [44]. In this way, localised
loss of BMP9 signalling would drive a corresponding local increase in PI3K–AKT–mTOR
signalling (Figure 2). Increased activation of PI3K is also seen when ACVRL1 levels are
reduced either in HHT2 patients or mouse models of HHT2 and targeting PI3K can protect
against AVM formation in the HHT2 neonatal mouse retina [17]. Important considerations
limiting translatability of these findings are uncertainty over which PI3K isoforms are
involved and clinically significant adverse effects of first generation PI3K inhibitors [70].
ECs lacking ENG protein show an increased rate of recycling of VEGFR2 to the
plasma membrane which may contribute to enhanced downstream VEGF signalling [37].
Intriguingly, ENG-depleted ECs show reduced VEGFR2 expression compared with wild
type cells, as well as reduced VEGFR2 phosphorylation in response to VEGF, yet still
show increased ERK and AKT activation downstream of VEGF stimulation [43,71]. An
added complexity is that a minimum of 2 h preincubation of cells with BMP9 can block
VEGF stimulated cell responses, suggesting there are yet unidentified downstream factors
involved in crosstalk between these two pathways [44]. These interactions are summarised
in Figure 2.
As targeting VEGF with Bevacizumab requires intravenous delivery, some investiga-
tions have focussed on orally effective receptor tyrosine kinase inhibitors (TKI) used in
oncology. These often target a broad range of growth factor receptors, and because HHT
studies have recruited either few or single cases it is too early to conclude whether these
provide a useful approach. The largest of these studies in seven HHT patients suggested
that the TKI Pazopanib gave some benefit in reducing epistaxis [52]. Ongoing larger trials
should provide firmer evidence in this area. In a preclinical model of HHT2, none of the
4 TKI drugs tested reduced wound-induced AVMs, but Sorafenib and a Pazopanib ana-
logue (GW771806) did significantly improved gastrointestinal bleeding [56]. An interesting
recent study has pointed to the power of a combination drug approach [54]. In mice with
HHT (due to antibody blockade of BMP9/10) with the receptor TKI, nintedanib, together
with the mTOR inhibitor, sirolimus, prevented as well as reversed retinal AVMs. This
same drug combination reduced gastrointestinal bleeding and anaemia in an independent
mouse model of HHT (inducible Acvrl1-deficient adult mice) [54].
In addition, VEGFR1 (also known as FLT1) acts as a natural decoy of VEGF signalling,
trapping the VEGF ligand away from the VEGFR2 receptor. HHT2 mice show downregula-
tion of VEGFR1 protein leading to enhanced VEGF signalling that will inevitably contribute
to abnormal endothelial responses [46,72].
5.4. β-Blockers
Arteriovenous shunts are high flow abnormalities that deliver blood at high pressure
into weak walled veins designed for low pressure flow. The small arteriovenous shunts in
mucosal telangiectases are at high risk of rupture, likely on the venous side. Thus, blood
pressure lowering medication may be beneficial. Propranolol, a nonselective β-blocker with
antiangiogenic effects, has shown some benefit used topically on nasal telangiectases [73],
although a double blind randomized placebo-controlled trial using topical application of
the β-blocker Timolol showed no benefit on epistaxis [53].
5.5. Enhancing Pericyte–Endothelial Cell Interactions
Although Thalidomide was temporarily taken off the market following the tragic
teratogenic outcomes when used to treat nausea in pregnant mothers in the 1960s, it has
recently shown promise as a treatment for epistaxis in HHT [38,74]. Thalidomide has
antiangiogenic effects by increasing EC–pericyte interactions. These cell–cell interactions
are disrupted following endothelial loss of ENG or ACVRL1 and Thalidomide appears to
compensate for this to increase vessel stability. Mechanistic understanding of this effect is
based on findings that loss of Eng in ECs leads to reduced crosstalk to adjacent muscle cells,
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leading to reduced downstream paracrine TGFβ signalling [75]. The resultant reduction
in vascular mural cell coverage in mouse models of HHT are rescued following increased
PdgfB expression stimulated by thalidomide [38,57]. However, in addition to its teratogenic
effects, thalidomide can induce irreversible neuropathy so less neurotoxic derivatives are
now under investigation.
The angiopoietin–Tie2 pathway is also critical for maintaining vessel stability.
Angiopoietin-1 (ANGPT1), produced by mural cells, activates the endothelial TIE2 re-
ceptor to maintain vascular smooth muscle cell (VSMC) coverage in mature blood vessels.
Following an inflammatory stimulus, ANGPT2 is rapidly released by ECs and inhibits
ANGPT1-mediated TIE2 activation, leading to destabilisation of the VSMC–endothelial
interaction and pericyte detachment. Interestingly, endothelial loss of Smad4 in mouse
leads to increased Angptl2 and downregulated Tie2 expression. The endothelial-specific
Smad4 null mouse model of HHT has an increased EC footprint and retinal AVM formation
that could be prevented by inhibiting ANGPT2 function with LC10 [58]. However, the
link to HHT remains to be clarified as circulating levels of ANGPT2 have been reported as
reduced in HHT patients [76].
6. Summary and Conclusions
Recent advances in understanding the biological basis of HHT and the development
of a range of preclinical models for drug testing has led to a gear change in efforts to find
effective treatments for HHT. Patient-specific therapies/personalised medicine options
may be required depending on individual disease symptoms and mutations. If similar
cellular and molecular changes cause both small telangiectases and larger AVMs, with
just a difference in scale, it is also possible that treatments targeting epistaxis may be
equally effective for attenuating AVM progression in major organs. Certainly, VEGF and
its downstream pathways are a major focus of current investigations along these lines.
Pharmaceutical treatment that could reverse the vessel remodelling in AVMs would be life
changing for HHT patients with severe morbidities. Finally, with better understanding of
the molecular and cellular defects in HHT lesions, there is real hope that effective therapies
are on the horizon.
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